Health Catalyst, Inc. (NASDAQ:HCAT) Shares Purchased by Impax Asset Management Group plc

Impax Asset Management Group plc raised its holdings in Health Catalyst, Inc. (NASDAQ:HCAT - Free Report) by 16.4% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 2,554,475 shares of the company's stock after purchasing an additional 360,201 shares during the quarter. Impax Asset Management Group plc owned about 4.22% of Health Catalyst worth $20,793,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in HCAT. Essex Investment Management Co. LLC purchased a new position in shares of Health Catalyst in the 1st quarter valued at approximately $1,848,000. ClariVest Asset Management LLC increased its stake in Health Catalyst by 303.9% in the 1st quarter. ClariVest Asset Management LLC now owns 282,325 shares of the company's stock valued at $2,126,000 after buying an additional 212,425 shares during the period. Susquehanna Fundamental Investments LLC purchased a new position in Health Catalyst during the 1st quarter worth $1,079,000. Inspire Investing LLC acquired a new stake in shares of Health Catalyst in the 1st quarter worth $355,000. Finally, Gruss & Co. LLC purchased a new stake in shares of Health Catalyst in the first quarter valued at about $188,000. Institutional investors and hedge funds own 85.00% of the company's stock.

Insider Activity at Health Catalyst

In other Health Catalyst news, COO Daniel Lesueur sold 5,209 shares of the firm's stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $7.68, for a total transaction of $40,005.12. Following the completion of the transaction, the chief operating officer now owns 134,899 shares of the company's stock, valued at approximately $1,036,024.32. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In related news, COO Daniel Lesueur sold 5,209 shares of the stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $7.68, for a total transaction of $40,005.12. Following the sale, the chief operating officer now owns 134,899 shares of the company's stock, valued at $1,036,024.32. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Kevin Lee Freeman sold 7,500 shares of the business's stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.22, for a total transaction of $54,150.00. Following the completion of the transaction, the insider now directly owns 255,881 shares of the company's stock, valued at $1,847,460.82. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 30,187 shares of company stock valued at $226,171. 2.50% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

HCAT has been the subject of several analyst reports. Stephens cut their price target on shares of Health Catalyst from $8.00 to $7.00 and set an "equal weight" rating for the company in a report on Thursday, August 8th. JPMorgan Chase & Co. increased their target price on Health Catalyst from $10.00 to $13.00 and gave the stock an "overweight" rating in a research note on Wednesday, September 4th. Cantor Fitzgerald restated an "overweight" rating and issued a $16.00 price target on shares of Health Catalyst in a research note on Friday, October 4th. Piper Sandler cut their price objective on Health Catalyst from $14.00 to $11.00 and set an "overweight" rating for the company in a research report on Monday, August 26th. Finally, Evercore ISI boosted their target price on shares of Health Catalyst from $8.00 to $10.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 8th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus target price of $11.90.

Health Catalyst Trading Up 1.0 %

Shares of HCAT stock traded up $0.08 during mid-day trading on Tuesday, reaching $7.76. The stock had a trading volume of 403,964 shares, compared to its average volume of 561,295. Health Catalyst, Inc. has a 12-month low of $5.42 and a 12-month high of $11.41. The business has a 50-day simple moving average of $7.98 and a 200 day simple moving average of $7.10. The company has a market cap of $469.25 million, a P/E ratio of -5.17 and a beta of 1.32.

Health Catalyst (NASDAQ:HCAT - Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported $0.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.08 by $0.04. The company had revenue of $75.90 million during the quarter, compared to analysts' expectations of $74.96 million. Health Catalyst had a negative net margin of 28.87% and a negative return on equity of 9.38%. The firm's quarterly revenue was up 3.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.21) earnings per share. Research analysts anticipate that Health Catalyst, Inc. will post -0.35 EPS for the current year.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.